% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@INPROCEEDINGS{Peplinski:1053904,
      author       = {Peplinski, Jana-Marie and Werner, Jan-Michael and Ceccon,
                      Garry and Wollring, Michael and Stetter, Isabelle and Rosen,
                      Jurij and Rosen, Elena and Kraft, Manuel and Fink, Gereon
                      and Langen, Karl-Josef and Lohmann, Philipp and Galldiks,
                      Norbert},
      title        = {{IMG}-61. {A}ssessment of18{F}-{FET} {PET}-based response
                      to bevacizumab-based regimens in patients with glioblastoma
                      at relapse using the {PET} {RANO} 1.0 criteria},
      issn         = {1523-5866},
      reportid     = {FZJ-2026-01602},
      year         = {2025},
      abstract     = {AbstractBACKGROUNDWe evaluated the amino acid PET-based
                      response assessment criteria (PET RANO 1.0) for their
                      ability to predict longer overall survival (OS) in patients
                      with glioblastoma treated with bevacizumab-based regimens at
                      relapse.PATIENTS AND METHODSThirty-eight adult patients with
                      IDH-wildtype glioblastoma were identified from three
                      previously published studies. All patients (i) received
                      bevacizumab in combination with a second agent (irinotecan,
                      lomustine, or nivolumab), (ii) underwent MRI- and
                      O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET imaging at
                      baseline and at a median time of 8 weeks (range, 4-12 weeks)
                      after treatment initiation, and (iii) had available
                      PET-derived parameters, i.e., metabolic tumor volume (MTV),
                      maximum and mean tumor-to-brain ratios (TBRmax and TBRmean).
                      A post-hoc analysis was performed to evaluate the predictive
                      value of the PET RANO 1.0 criteria. In addition, ROC
                      analyses were performed to define PET parameter thresholds
                      for predicting an OS≥9 months. Furthermore, response
                      prediction using the RANO 2.0 criteria for MRI was compared
                      with the PET RANO 1.0 criteria.RESULTSAccording to the PET
                      RANO 1.0 criteria, patients fulfilling the criterion Stable
                      Disease (n=10), Partial Response (n=19), or Complete
                      Response (n=1) had a significantly longer OS than patients
                      with Progressive Disease (n=8) (9.0 vs. 4.0 months;
                      P=0.001). Among the suggested thresholds by the PET RANO 1.0
                      criteria, only a MTV reduction $≥40\%$ was significantly
                      predictive of response (7.3 vs. 4.0 months; P=0.008).
                      Optimal thresholds identified by ROC analysis differed from
                      those proposed by the PET RANO 1.0 criteria. A reduction in
                      MTV by $≥30\%$ and in TBRmean by $≥4\%$ were both
                      predictive of longer OS (7.3 vs. 4.0 months; P=0.008, and
                      10.6 vs. 6.0 months; P=0.010, respectively). The RANO 2.0
                      criteria were less significant to predict a longer OS (9.0
                      vs. 6.0 months; P=0.015).CONCLUSIONPET RANO 1.0 criteria
                      appear to be effective in predicting response to
                      bevacizumab-based therapy in glioblastomas at relapse.},
      month         = {Nov},
      date          = {2025-11-20},
      organization  = {7th Quadrennial Meeting of the World
                       Federation of Neuro-Oncology Societies,
                       Honolulu (USA), 20 Nov 2025 - 23 Nov
                       2025},
      cin          = {INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-4-20090406},
      pnm          = {5253 - Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)1},
      doi          = {10.1093/neuonc/noaf201.1140},
      url          = {https://juser.fz-juelich.de/record/1053904},
}